最新ニュース Natera (NASDAQ:NTRA) 株価情報

NATERA INC

Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Natera Inc

UBS analyst Elizabeth Garcia maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Buy and raises the price target from $211 to $218.

News

Price Target

Analyst Ratings

NTRA

UBS Maintains Buy on Natera, Raises Price Target to $218

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $194.25, a high estimate of $251.00, and a low estimate of $160.00. This upward trend is apparent, with the current average reflecting a 6.32% increase from the previous average price target of $182.71.
<img src="https://www.benzinga.com/files/images/story/2025/1746799285_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive Natera is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$251.00</td>
<td>-</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$188.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Natera. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Natera compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Natera's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Natera's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Natera analyst ratings.</a>
<h2>Discovering Natera: A Closer Look</h2>
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
<h3>Understanding the Numbers: Natera's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Natera's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 53.02%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Natera's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -11.29%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -5.19%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Natera's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -3.31%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.16.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

8 Analysts Have This To Say About Natera

Barclays analyst Luke Sergott maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $160 to $190.

Barclays Maintains Overweight on Natera, Raises Price Target to $190

WIIM

Natera shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance above estimates.

Guidance

Natera Raises FY2025 Sales Guidance from $1.87B-$1.95B to $1.94B-$2.02B vs $1.92B Est

Earnings

Earnings Beats

Natera Q1 EPS $(0.50) Beats $(0.64) Estimate, Sales $501.83M Beat $446.27M Estimate

Demonstrates Signatera's ability to predict long-term outcomes in early-stage, high-risk breast cancers
Several datasets will be presented, highlighting Natera's leadership in breast cancer MRD
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54251382&amp;newsitemid=20250507368666&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=983f3b8f78ef5c548d7c881b54d9f004">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025.
Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap Healthcare Collaborative, will be shared in a mini-oral presentation on May 16, 2025. The report includes data from 712 patients with early-stage, high-risk breast cancer, and it evaluates the association of distant recurrence free survival (DRFS) with ctDNA concentration at diagnosis, before receiving neoadjuvant systemic therapy and curative-intent surgery.

Natera To Present Multiple Datasets In Breast Cancer Together With Collaborators At 2025 ESMO Breast Cancer Annual Congress In Munich

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Natera to report an earnings per share (EPS) of $-0.66.
The announcement from Natera is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
The company's EPS missed by $0.02 in the last quarter, leading to a 0.65% drop in the share price on the following day.
Here's a look at Natera's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.39</td>
<td>-0.57</td>
<td>-0.69</td>
<td>-0.70</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.41</td>
<td>-0.26</td>
<td>-0.30</td>
<td>-0.56</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>19.0%</td>
<td>6.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746626477_0.png" alt="eps graph" />
<h3>Market Performance of Natera's Stock</h3>
Shares of Natera were trading at $155.5 as of May 06. Over the last 52-week period, shares are up 63.32%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Take on Natera</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Natera.
A total of 7 analyst ratings have been received for Natera, with the consensus rating being Outperform. The average one-year price target stands at $194.86, suggesting a potential 25.31% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of and Natera, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary presents essential metrics for and Natera, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natera</td>
<td>Outperform</td>
<td>53.02%</td>
<td>$299.64M</td>
<td>-5.19%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Natera's consensus rating is "Outperform," indicating positive market sentiment. It ranks first in revenue growth among its peers, with a growth rate of 53.02%. However, it has the lowest gross profit margin at $299.64M. Additionally, Natera has the lowest return on equity at -5.19%, suggesting lower profitability compared to its peers.
<h3>Unveiling the Story Behind Natera</h3>
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
<h3>Natera's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Natera's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 53.02% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -11.29%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Natera's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.19%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Natera's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.31%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Natera's debt-to-equity ratio is below the industry average at 0.16, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/NTRA/earnings">To track all earnings releases for Natera visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Natera's Earnings

<ul>
<li>Study published in American Journal of Transplantation highlights strong sensitivity and specificity, along with a &gt;37% reduction in false positives when using Prospera Heart with DQS</li>
<li>Adds to the growing body of evidence supporting DQS for dd-cfDNA analysis in solid organ transplant</li>
</ul>

Natera's Prospera Heart With DQS Cuts False Positives By Over 37%, Outperforming dd-cfDNA Percentage Alone, AJT Publication Shows

Stanford-led study included over 2,100 Signatera samples from over 200 sarcoma patients, with overall sensitivity of 89% and specificity of 100%
Leiomyosarcoma, the most common subtype in the cohort, demonstrated sensitivity of 93% and specificity of 100%

Natera's Signatera Shows 93% Sensitivity In Leiomyosarcoma, Most Common Sarcoma Subtype In Study

Natera's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NYSE">NTRA</a>) short percent of float has risen 7.64% since its last report. The company recently reported that it has 6.01 million shares sold short, which is 4.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.4 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Natera Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746201630_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Natera has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Natera's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Natera's peer group average for short interest as a percentage of float is 6.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Natera's Recent Short Interest

NTRA stock has given up its prior loss. Natera shares were trading lower. The company reported results from its DEFINE-HT clinical trial.

Natera shares are trading lower. The company reported results from its DEFINE-HT clinical trial.

ProsperaHeart with donor quantity score (DQS) demonstrates significant correlation with clinical outcomes
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54246141&amp;newsitemid=20250429528308&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=256696dd468270ee171db9cc0e8d0e19">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, announced the results of its DEFINE-HT clinical trial in heart transplantation, which were shared today, April 29, 2025, in an oral presentation at the International Society for Heart and Lung Transplantation 45th Annual Meeting in Boston, MA.
DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-derived cell-free DNA (dd-cfDNA), as measured by Prospera Heart with DQS, are associated with adverse clinical outcomes. Following heart transplant, Prospera testing was performed concurrently with rejection surveillance monitoring, including endomyocardial biopsies (EMB), for up to one year.
Findings from the study, which included more than 1,100 dd-cfDNA samples, demonstrated that dd-cfDNA significantly correlated with adverse outcomes, a composite endpoint defined as the total number of treated rejections, graft dysfunctions, re-transplantations, and deaths at one year after heart transplant.

Natera: Results Of DEFINE-HT Clinical Trial Shows Prospera Heart Is Predictive Of Clinical Outcomes And Outperforms Biopsy In Predicting Graft Dysfunction

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 20.08% on an annualized basis producing an average annual return of 34.44%. Currently, Natera has a market capitalization of $20.69 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $415.77 today based on a price of $153.03 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745848826_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Extensive pan-cancer validation data from over 3,000 plasma samples to be presented at ASCO
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54243019&amp;newsitemid=20250424920561&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=9c36e2d7b0648c477e4e23a940d6b1d2">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly available to physicians in the United States.
This launch is supported by a large genome-based molecular residual disease (MRD) study, which was accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. In this clinical validation study of more than 3,000 samples from multiple cancer types – including breast cancer, colorectal cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma – Signatera Genome was able to detect circulating tumor DNA (ctDNA) significantly ahead of clinical recurrence with excellent performance. In addition, postsurgical Signatera-positive patients had inferior recurrence-free survival compared to Signatera-negative patients, consistently across the different cancers that were evaluated. Additional clinical utility data on the Signatera Genome assay, including predictive data, will be presented at the conference.
Signatera Genome is available in CLIA, IUO and RUO and was designed to improve patient management as an ultra-sensitive assay for the detection of ctDNA. The test's bespoke assay is designed from a whole genome sequence of a patient's tumor and matched normal DNA. It benefits from Natera's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.natera.com%2Fcompany%2Fnews%2Fnatera-expands-intellectual-property-portfolio-with-new-patents-in-tumor-informed-mrd%2F&amp;esheet=54243019&amp;newsitemid=20250424920561&amp;lan=en-US&amp;anchor=patented&amp;index=2&amp;md5=9185737f23159d28b6c15068250d6793">patented</a> multiplex polymerase chain reaction and next generation sequencing technology (mPCR-NGS), using a targeted and deep sequencing approach to detect tiny traces of tumor DNA at frequencies as low as 1 part per million (PPM). An RUO version of the assay is available that detects below 1 PPM.
"We are extremely pleased with the emerging evidence for our Signatera Genome assay, providing an ultrasensitive MRD detection tool for physicians," said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer. "We look forward to sharing the results of this study, which further demonstrates the clinical utility of Signatera across disease indications."

Biotech

General

Natera Announces That Its Ultra-Sensitive Signatera Genome Assay Is Now Broadly Available To Physicians In The United States.

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 19.34% on an annualized basis producing an average annual return of 33.37%. Currently, Natera has a market capitalization of $20.02 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $423.33 today based on a price of $148.08 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744926311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today

Analysts' ratings for Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Natera, presenting an average target of $195.4, a high estimate of $251.00, and a low estimate of $160.00. Witnessing a positive shift, the current average has risen by 7.88% from the previous average price target of $181.12.
<img src="https://www.benzinga.com/files/images/story/2025/1744315217_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Natera's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $160.00&#x7C;$200.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Announces &#x7C;Outperform &#x7C; $251.00&#x7C;- &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $185.00&#x7C;$176.00 &#x7C; 
&#x7C;David Westenberg &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $205.00&#x7C;$200.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $195.00&#x7C;$180.00 &#x7C; 
&#x7C;Catherine Ramsey &#x7C;Baird &#x7C;Raises &#x7C;Outperform &#x7C; $188.00&#x7C;$183.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Maintains &#x7C;Buy &#x7C; $180.00&#x7C;$180.00 &#x7C; 
&#x7C;Matthew Sykes &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $190.00&#x7C;$160.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Announces &#x7C;Overweight &#x7C; $200.00&#x7C;- &#x7C; 
&#x7C;Subbu Nambi &#x7C;Guggenheim &#x7C;Raises &#x7C;Buy &#x7C; $200.00&#x7C;$170.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Natera. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Natera compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Natera's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Natera's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Natera analyst ratings.</a>
<h2>About Natera</h2>
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
<h3>A Deep Dive into Natera's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Natera displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 53.02%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -11.29%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Natera's ROE excels beyond industry benchmarks, reaching -5.19%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Natera's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -3.31%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Natera's debt-to-equity ratio is below the industry average. With a ratio of 0.16, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Natera: Insights From 10 Financial Analysts

Barclays analyst Luke Sergott maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and lowers the price target from $200 to $160.

Barclays Maintains Overweight on Natera, Lowers Price Target to $160

Press Releases

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

Natera to Report its First Quarter Results on May 8, 2025

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

Comments

Natera

ニュース

最新ニュース Natera (NASDAQ:NTRA) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル